Dyne Therapeutics
dyne-tx.com
Actively hiring
Rare Disease Therapeutics
Prescription Drugs
As featured in
View 10 jobs
Claim pageClaim
Follow
Overview
Connections
News
Technologies
Salaries
Products
People
Growth
Offices
Jobs
Financials
How Dyne Therapeutics hires
Truth index
A 87/100
Median time to fill
89 days
Ghost roles
0%
Stale roles
33%
Reposted roles
0%
Dyne Therapeutics scores A on the Alion truth index (A is best, E worst), measured over 3 open roles re-checked against its own hiring board: 0% look like ghost listings, 33% have gone stale and 0% are the same role posted again. Its roles close in a median of 89 days. It measures how much of what this employer publishes turns into a real, finite search - not the employer as a workplace. How the index is computed
Overview
Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD).
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
MPM BioImpactVia a fund
Atlas VentureVia a fund
Wellington ManagementVia a fund
RA Capital ManagementVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Do Dyne Therapeutics' (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative?
Dyne Therapeutics announced it will present additional one-year clinical data from its Phase 1/2 ACHIEVE trial of zeleciment basivarsen for myotonic dystrophy type 1 at upcoming World Muscle Society and AANEM meetings in late September and early October 2
Read more
Report
Dyne Therapeutics Shares Fall 29% As DM1 Rival Fails Phase 3; One-Year Data Ahead
Dyne Therapeutics shares fell 29% after Novartis' Phase 3 DM1 trial failed. Dyne plans to present six- and 12-month ACHIEVE data for z-basivarsen at WMS and AANEM, ahead of a Q1 2027 topline readout.
Read more
Report
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting
- Data support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 53, 45, 44 or 55, all of which are advancing into IND-enabling studies - - All development candidates leverage the same FORCE platform as zeleci
Read more
Report
Dyne Therapeutics (DYN) Inspires Confidence With Its Force Platform
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 affordable biotech stocks to buy right now. On June 26, TD Cowen initiated its coverage of Dyne Therapeutics Inc. (NASDAQ:DYN), assigning a Buy rating to the stock. The firm stated that the company's Fo
Read more
Report
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss market. See how their financials and risk profiles compare.
Read more
Report
Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets
A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare - and the timing may be the entire story.
Read more
Report
Show more news
Tech stack
Technologies named in job postings at Dyne Therapeutics over the last 12 months, by layer, with the share of postings for each.
Technologies in use
15
Postings analysed
14
Stack modernity
54/100
Languages
SAS7%
Cloud & platforms
GCP43%
Power BI7%
Tableau7%
Sign in to see how your skills match this stack
Sign In
Full Dyne Therapeutics tech stack
15 technologies · by team · pay by technology · changes · similar stacks
Salary insights
Compensation ranges based on this company's open jobs
Median
$230k
Typical range
$120k – $318k
Open positions
16
16
Jobs
Senior
25%
Staff
18.8%
Architect
56.3%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Senior | 4 | $230k | $120k – $300k |
| Staff | 3 | $200k | $150k – $225k |
| Architect | 9 | $230k | $195k – $318k |
Highest paying role
Executive Director, Regulatory Affairs
$318k
Normalized to USD per year
All salaries at Dyne Therapeutics
By role, level and city, against the market · 16 jobs with pay
People
Richard Scalzo
Executive Officer
Joshua Brumm
Executive Officer, Director
Jonathan McNeill M.D.
Executive Officer
Oxana Beskrovnaya Ph.D.
Executive Officer
Romesh Subramanian Ph.D.
Executive Officer
Lawrence Klein Ph.D.
Director
David Lubner
Director
Edward Hurwitz
Director
Dirk Kersten
Director
Catherine Stehman-Breen M.D.
Director
Jason Rhodes
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Growth
Hiring Momentum
65/100
Growing
Open positions
16
4 opened / 18 closed in 30 days
Median time-to-fill
89 days
faster than 14% of the market
ATS activity
Every ~4 hours
Today
Hiring Dynamics
+2000%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Biotech
24% ▲
Finance
19% ▲
HR
14% ▼
Science & Research
14% ▼
Administrative
10% ▲
Leadership
5% ▲
Actively hiring for Finance (+3 in 30 days)
Activity Timeline
Added SharePoint to stack
Oct 2026
Added Good Clinical Practice to stack
Oct 2026
Added Tableau to stack
Oct 2026
Added Power BI to stack
Oct 2026
Added 21 CFR Part 11 to stack
Oct 2026
Added SAS to stack
Oct 2026
Added CAPA to stack
Oct 2026
Added Veeva to stack
Oct 2026
Added ICH Guidelines to stack
Oct 2026
Added GLP to stack
Oct 2026
Added Mass Spectrometry to stack
Oct 2026
Added HPLC to stack
Oct 2026
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Waltham
Waltham
United States
HQ
Waltham, MA
14 open roles 20 posted in 90 days 200-500 est. staff $221k Avg Salary
hires for Biotech, Leadership, Administrative
1560 Trapelo Road, Waltham, MA 02451
Jobs
$160k – $200k per year · In office · Full-Time · 8+ years exp · Bachelor's Degree · Waltham
HPLC
Chromatography
GMP
MedTech
CAPA
Apply
$265k – $300k per year · In office · 12+ years exp · PhD · Waltham
SAS
Apply
$165k – $200k per year · In office · 8+ years exp · Waltham
GCP
Life Sciences
Good Clinical Practice
MedTech
CAPA
Apply
$294k – $318k per year · In office · 18+ years exp · Bachelor's Degree · Waltham
Apply
$220k – $240k per year · In office · 10+ years exp · PhD · Waltham
GCP
Apply
$190k – $235k per year · Remote (likely United States) · 10+ years exp · Bachelor's Degree
GCP
Management
SharePoint
Apply
$165k – $190k per year · In office · 7+ years exp · PhD · Waltham
Apply
$190k – $235k per year · Remote (likely United States) · 10+ years exp · Bachelor's Degree
GCP
Management
SharePoint
Apply
Apply
$160k – $195k per year · In office · 8+ years exp · Bachelor's Degree · Waltham
GCP
Life Sciences
GMP
GLP
ICH Guidelines
Veeva
Apply